For perfusion imaging TECHNEGAS. Sold as Technegas. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Technetium Tc-99m Labeled Carbon (sold as Technegas), first approved Sep 29, 2023, with 0 new uses approved and 1 published complete response letter.
| Study | Phase | Status | Posted |
|---|---|---|---|
| PAXT: Pulmonary Imaging of Mild Asthma Using 129Xe MRI and Tc-99-Labeled-Carbon-Imaging (Tc99CImaging)Mild Asthma · Dr. Grace Parraga | — | Recruiting | Aug 27, 2025 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Sep 29, 2023 | TechnegasNDA 22335 · New dosage form | Cyclomedica | 0 | Marketed |
| Letter | Product | Now |
|---|---|---|
| Jun 25, 2021 | Technegas Technetium Tc-99m carbonProduct Quality, Facility Inspections | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA